Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One

NCT00530348 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

581

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

BIOLOGICAL: Alemtuzumab
BIOLOGICAL: Interferon beta-1a

Sponsor

Genzyme, a Sanofi Company

Collaborators

[object Object]